Frequency of adverse events in ponatinib-treated patients. (A) New-onset non-CAEs increased in a ponatinib dose-dependent fashion. (B) New-onset CAEs were fewer in comparison with non-CAEs. The most common CAEs were arrhythmia and hypertension.